Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
about
Anti-nerve growth factor in pain management: current evidenceDissociation between the relief of skeletal pain behaviors and skin hypersensitivity in a model of bone cancer pain.Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept studyCelecoxib for osteoarthritis.Monoclonal antibodies for the treatment of osteoarthritis.Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?A Mechanism-Based Approach to the Management of Osteoarthritis PainEfficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.Osteoarthritis year in review 2015: clinical.Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administrationSelective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis.Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.Development of nerve growth factor (NGF) inhibition as a strategy for treatment of pain.Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?Tanezumab in the treatment of chronic musculoskeletal conditions.Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis.Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain.Use of strong opioids for chronic pain in osteoarthritis: an insight into the Latin American reality.[EXPRESS] Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications.The TrkA receptor mediates experimental thermal hyperalgesia produced by nerve growth factor: Modulation by the p75 neurotrophin receptor.Native joint-resident mesenchymal stem cells for cartilage repair in osteoarthritis.Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.What is new in pain modification in osteoarthritis?Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis.Therapeutics in Osteoarthritis Based on an Understanding of Its Molecular Pathogenesis.Role of the Bone Microenvironment in the Development of Painful Complications of Skeletal Metastases.First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain.
P2860
Q26746194-80143574-1487-4198-A0E1-6365FD9CA6E2Q30831131-7AF85763-D4A6-416C-8E20-4A36EEC504A6Q34140663-40E4F403-F2B8-4116-8086-8E1E0BBDAABFQ34557021-CBE8C14B-8BCD-4953-AFB4-CBD6B9596BC0Q36113839-60D45A9A-6AFD-4CE1-8781-6ECCC28A1D44Q36183809-78C0BBC6-52B5-4B53-995F-5BEDBA5FCA93Q36217637-DD41AE49-B67A-4A79-B348-5328B460850EQ36236043-5DDA3D06-176F-42C9-ACDC-1B9CA261A600Q36409343-4732AA0A-9FC5-400E-83CD-08E7605ACE94Q36818355-6B45FDF5-D4F1-4EAD-9032-3AF24E228DE7Q36871346-3532E899-4E45-4E1B-99C3-8411334A8D81Q37604491-24F51B18-1D59-4B7B-9585-5C22368B318AQ38255624-E2F98637-5D31-44AA-8655-1B22FDC3A2C9Q38817280-9673F403-DC14-4171-AAFD-E9C50A6E2592Q39034462-066A5DE6-079F-4D8B-8888-78A782B346C7Q39184757-96E07081-9430-4121-B492-06A01B8EC3B7Q39195605-B64E7347-A0D4-4756-A4A3-4C634423432EQ43076011-AFFE3B8F-9481-49FE-8BAE-6556DB4F9470Q46156381-374F79E6-CD97-4687-A06A-029D98044D08Q47159403-36A29113-82FC-460F-8849-35FA2F53B2F3Q47629559-1BFE1AF5-295F-4733-AB28-B0143182E1BEQ47717163-59112B82-920C-451D-9E95-329C3B1C0414Q48526597-84080389-EFA8-4B01-B008-FFD7294E48B1Q49402122-AD817396-088E-4662-A617-02E1112CFAADQ52679053-B5781FA0-6559-4EE4-9CEB-02D5A5451A88Q54940744-B61F8F05-F1F2-4C79-87B0-8435DA650B7CQ55264146-5526D1AA-4E87-43C9-ACC8-5A189EA6CB80
P2860
Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Efficacy and safety of tanezum ...... ee or hip osteoarthritis pain.
@en
Efficacy and safety of tanezum ...... ee or hip osteoarthritis pain.
@nl
type
label
Efficacy and safety of tanezum ...... ee or hip osteoarthritis pain.
@en
Efficacy and safety of tanezum ...... ee or hip osteoarthritis pain.
@nl
prefLabel
Efficacy and safety of tanezum ...... ee or hip osteoarthritis pain.
@en
Efficacy and safety of tanezum ...... ee or hip osteoarthritis pain.
@nl
P2093
P2860
P1476
Efficacy and safety of tanezum ...... ee or hip osteoarthritis pain.
@en
P2093
Christine R West
Egilius L H Spierings
Evan F Ekman
H Scott Greenberg
Kenneth M Verburg
Mark T Brown
Michael D Smith
Thomas J Schnitzer
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-204905
P407
P577
2014-03-13T00:00:00Z